January 2022—Co-Diagnostics has entered into definitive agreements with Idaho Molecular and Advanced Conceptions in which both companies will become wholly owned subsidiaries of Co-Dx. Salt Lake City–based Co-Dx has been working with Idaho Molecular and Advanced Conceptions on the development of Co-Dx’s at-home, point-of-care diagnostic device. The transactions will provide Co-Dx with existing and future assets and intellectual property related to the platform.
Read More »